BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24536001)

  • 1. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl.
    Besbas N; Gulhan B; Gucer S; Korkmaz E; Ozaltin F
    J Nephrol; 2014 Aug; 27(4):457-60. PubMed ID: 24536001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab for dense deposit disease and C3 glomerulonephritis.
    Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
    Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
    Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
    J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
    Licht C; Fremeaux-Bacchi V
    Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 glomerulopathy: what's in a name?
    D'Agati VD; Bomback AS
    Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry.
    Medjeral-Thomas N; Malik TH; Patel MP; Toth T; Cook HT; Tomson C; Pickering MC
    Kidney Int; 2014 Apr; 85(4):933-7. PubMed ID: 24067434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FHR-5 Serum Levels and
    Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
    Front Immunol; 2021; 12():720183. PubMed ID: 34566977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology after eculizumab in dense deposit disease and C3 GN.
    Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
    J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up.
    Figuères ML; Frémeaux-Bacchi V; Rabant M; Galmiche L; Marinozzi MC; Grünfeld JP; Noël LH; Servais A
    Hum Pathol; 2014 Nov; 45(11):2326-33. PubMed ID: 25260719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
    Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
    Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency.
    Vernon KA; Goicoechea de Jorge E; Hall AE; Fremeaux-Bacchi V; Aitman TJ; Cook HT; Hangartner R; Koziell A; Pickering MC
    Am J Kidney Dis; 2012 Jul; 60(1):121-5. PubMed ID: 22503529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).
    Abrera-Abeleda MA; Nishimura C; Smith JL; Sethi S; McRae JL; Murphy BF; Silvestri G; Skerka C; Józsi M; Zipfel PF; Hageman GS; Smith RJ
    J Med Genet; 2006 Jul; 43(7):582-9. PubMed ID: 16299065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membranoproliferative glomerulonephritis with isolated C3 deposits: case report and literature review.
    Darouich S; Goucha R; Jaafoura MH; Zekri S; Kheder A; Ben Maiz H
    Ultrastruct Pathol; 2011 Feb; 35(1):42-6. PubMed ID: 21265634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
    Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.